US FDA accepts Glenmark’s IND application for GRC 54276 to proceed with Phase 1/2 clinical study for…
GRC54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor developed by Glenmark
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
IND application
Zydus Cadila files IND application for ZYIL1, NLRP3 inflammasome inhibitor
It can selectively modulate the inflammatory responses caused by the ‘Cytokine Storm’ in ARDS, COVID19 and other inflammatory…
USFDA approves IND application from Reven Pharma for Rejuveinix to treat COVID-19
RJX is an IV formulation being developed for treatment of inflammatory disorders, including COVID-19 patients with viral sepsis,…
ARCA biopharma submits IND application to US FDA for a potential COVID-19 treatment
Pending FDA feedback, ARCA anticipates initiating the Phase 2b portion of a sequential Phase 2b/3 clinical evaluation of AB201 in…
Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program
Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…